In recent years, with increasing understanding of psoriasis pathogenesis, biological agents that target interleukin (IL)-17, IL-23, and tumor necrosis factor-alpha have been widely applied for the treatment of psoriasis (Lee and Kim, 2023; Wride et al., 2024). Here, IL17A is linked to psoriasis.